PTC Therapeutics Inc PTCT

NAS: PTCT | ISIN: US69366J2006 30/04/2025

49,84 USD (+0,65%)

(+0,65%) 30/04/2025

Grafiek PTC Therapeutics Inc

Grafiek PTC Therapeutics Inc

1 dag1d 0,65%
1 week1w 0,59%
1 maand1m 6,95%
3 maanden3m -0,34%
6 maanden6m 23,15%
1 jaar1j 45,90%
5 jaar5j 3,83%

dinsdag 6 mei 2025, 22:00

Kwartaalcijfers (1ste kwartaal)

PTC Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

25 april 2025 · PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) · Persbericht

24 april 2025 · PTC Therapeutics to Participate at Upcoming Investor Conferences · Persbericht

17 april 2025 · PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results · Persbericht

28 maart 2025 · PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

28 maart 2025 · PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe · Persbericht

20 maart 2025 · PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies · Persbericht

12 september 2024 · PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

28 augustus 2024 · PTC Therapeutics to Participate at Upcoming Investor Conferences · Persbericht

8 augustus 2024 · PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results · Persbericht

30 juli 2024 · PTC Therapeutics Announces Sepiapterin NDA Submission to FDA · Persbericht

Profiel PTC Therapeutics Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.ptcbio.com

Hoofdzetel: South Plainfield, New Jersey Verenigde Staten

CEO: Stuart Peltz

Werknemers: 1.467

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe